Mr Bernard Robinson, MD | |
91-2139 Fort Weaver Rd, Suite 210, Ewa Beach, HI 96706-3607 | |
(808) 680-0554 | |
(808) 680-0500 |
Full Name | Mr Bernard Robinson |
---|---|
Gender | Male |
Speciality | Neurological Surgery |
Location | 91-2139 Fort Weaver Rd, Ewa Beach, Hawaii |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1063517233 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207T00000X | Neurological Surgery | MD-4524 (Hawaii) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Bernard Robinson, MD 98-944 Kahapili Street, Aiea, HI 00009-6701 Ph: (808) 488-8698 | Mr Bernard Robinson, MD 91-2139 Fort Weaver Rd, Suite 210, Ewa Beach, HI 96706-3607 Ph: (808) 680-0554 |
News Archive
NYU Langone Medical Center today announced its plan to transform its Emergency Department (ED) into a state-of the-art emergency facility to meet the growing need for emergency care services in the community. Once completed, the new facility will nearly triple the size of the current ED and will include for the first time a separate area dedicated to pediatric emergency services.
The GAVI Alliance has appealed to donors for $3.7 billion to be pledged during an upcoming conference despite announcements by several major pharmaceutical companies to lower the prices of their vaccines for childhood diseases, the Associated Press/Washington Post reports.
In the study, which appeared on the pre-print server medRxiv*, the team also modeled the pandemic phases with exponential growth and decay. The model improves upon maximum likelihood estimates by conditioning on more data.
UCSF researchers have shown for the first time that the human fetal immune system arises from an entirely different source than the adult immune system, and is more likely to tolerate than fight foreign substances in its environment.
Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, today announced that it has closed on a $10 million tranche of a Series B financing, based on substantial progress with the company's product pipeline including advancing the lead product candidate, TT30, toward clinical development.
› Verified 5 days ago